Astellas Pharma Inc. - Product Pipeline Review - 2014

Published: Sep, 2014 | Pages: 247 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Astellas Pharma Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Astellas Pharma Inc. - Product Pipeline Review - 2014', provides an overview of the Astellas Pharma Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Astellas Pharma Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Astellas Pharma Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Astellas Pharma Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Astellas Pharma Inc.'s pipeline products

Reasons to buy

- Evaluate Astellas Pharma Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Astellas Pharma Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Astellas Pharma Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Astellas Pharma Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Astellas Pharma Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Astellas Pharma Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Astellas Pharma Inc. Snapshot 7
Astellas Pharma Inc. Overview 7
Key Information 7
Key Facts 7
Astellas Pharma Inc. - Research and Development Overview 8
Key Therapeutic Areas 8
Astellas Pharma Inc. - Pipeline Review 16
Pipeline Products by Stage of Development 16
Pipeline Products - Monotherapy 17
Pipeline Products - Combination Treatment Modalities 18
Pipeline Products - Partnered Products 19
Pipeline Products - Out-Licensed Products 21
Astellas Pharma Inc. - Pipeline Products Glance 23
Astellas Pharma Inc. - Late Stage Pipeline Products 23
Astellas Pharma Inc. - Clinical Stage Pipeline Products 26
Astellas Pharma Inc. - Early Stage Pipeline Products 28
Astellas Pharma Inc. - Drug Profiles 32
enzalutamide 32
isavuconazonium sulfate 35
nateglinide + DPP-4 Inhibitor 37
tacrolimus ER 38
(mirabegron + solifenacin succinate) 39
amenamevir 40
ASP-0113 41
bendamustine hydrochloride 42
beraprost sodium LA 44
bixalomer 47
degarelix 49
evolocumab 51
fidaxomicin 53
ipragliflozin 56
peficitinib 59
quetiapine fumarate ER 60
rilotumumab 61
romosozumab 63
roxadustat 65
solifenacin succinate 67
tacrolimus 70
ASP-1707 71
ASP-3652 72
ASP-4901 73
ASP-7991 74
ASP-8477 75
erlotinib hydrochloride 76
FG-2216 79
linaclotide 81
regadenoson 84
AMG-337 86
ASP-8273 87
gilteritinib 88
linsitinib 89
AGS-15E 92
AGS-16C3F 93
AGS-16M8F 94
AGS-67E 95
ASG-15ME 96
ASP-3325 97
ASP-3662 98
ASP-3700 99
ASP-5633 100
ASP-5878 101
ASP-7657 102
ASP-7962 103
ASP-8232 104
ASP-9226 105
enfortumab vedotin 106
mirabegron ER 108
OSI-027 110
OSI-930 111
Antibody Drug Conjugates for Cancer 112
AS-1069562 113
AS-1535907 114
AS-1669058 115
AS-1708727 116
AS-1842856 117
AS-1940477 118
AS-2034178 119
AS-2077715 120
AS-2444697 121
AS-2521780 122
AS-2575959 123
AS-2690168 124
AS-2715348 125
AS-2795440 126
ASP-1017 127
ASP-3258 128
ASP-6537 129
ASP-7663 131
ASP-9133 132
ASP-9726 133
EMSP 135
ESB 136
ESBB 137
FK-886 138
KB-425796C 140
Monoclonal Antibody Conjugates for Oncology 141
Monoclonal Antibody For Infectious Diseases 142
MSP 143
OSI-296 144
PQIP 146
Small Molecule to Inhibit 17-Beta-HSD for Castration-Resistant Prostate Cancer 147
Small Molecule to Inhibit TAK1 for Ovarian Cancer 148
Small Molecules to Agonize GPR119 Receptor for Type 2 Diabetes 149
Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine 150
Small Molecules to Inhibit DAAO for Cognitive Disorders 151
Small Molecules to Inhibit RANKL for Osteoclastogenesis 152
Small Molecules to Inhibit VAP-1 for Diabetic Macular Edema 153
Vaccine For RSV 154
ASP-2397 155
Drug For Alzheimer's Disease 156
Drugs for Pancreatic Cancer 157
KB-425796A 158
Monoclonal Antibodies for Cancer 159
Small Molecule to Inhibit PDE10A for Schizophrenia 160
Small Molecules For Neglected Tropical Diseases 161
Small Molecules to Inhibit ACK1 for Cancer 162
Astellas Pharma Inc. - Pipeline Analysis 163
Astellas Pharma Inc. - Pipeline Products by Target 163
Astellas Pharma Inc. - Pipeline Products by Route of Administration 167
Astellas Pharma Inc. - Pipeline Products by Molecule Type 168
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action 169
Astellas Pharma Inc. - Recent Pipeline Updates 173
Astellas Pharma Inc. - Dormant Projects 217
Astellas Pharma Inc. - Discontinued Pipeline Products 219
Discontinued Pipeline Product Profiles 220
Astellas Pharma Inc. - Company Statement 228
Astellas Pharma Inc. - Locations And Subsidiaries 231
Head Office 231
Other Locations & Subsidiaries 231
Astellas Pharma Inc. - Key Manufacturing Facilities 237
Appendix 238
Methodology 238
Coverage 238
Secondary Research 238
Primary Research 238
Expert Panel Validation 238
Contact Us 239
Disclaimer 239

List of Tables
Astellas Pharma Inc., Key Information 15
Astellas Pharma Inc., Key Facts 15
Astellas Pharma Inc. - Pipeline by Indication, 2014 18
Astellas Pharma Inc. - Pipeline by Stage of Development, 2014 24
Astellas Pharma Inc. - Monotherapy Products in Pipeline, 2014 25
Astellas Pharma Inc. - Combination Treatment Modalities in Pipeline, 2014 26
Astellas Pharma Inc. - Partnered Products in Pipeline, 2014 27
Astellas Pharma Inc. - Partnered Products/ Combination Treatment Modalities, 2014 28
Astellas Pharma Inc. - Out-Licensed Products in Pipeline, 2014 29
Astellas Pharma Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2014 30
Astellas Pharma Inc. - Pre-Registration, 2014 31
Astellas Pharma Inc. - Filing rejected/Withdrawn, 2014 32
Astellas Pharma Inc. - Phase III, 2014 33
Astellas Pharma Inc. - Phase II, 2014 34
Astellas Pharma Inc. - Phase I, 2014 35
Astellas Pharma Inc. - IND/CTA Filed, 2014 36
Astellas Pharma Inc. - Preclinical, 2014 37
Astellas Pharma Inc. - Discovery, 2014 39
Astellas Pharma Inc. - Pipeline by Target, 2014 172
Astellas Pharma Inc. - Pipeline by Route of Administration, 2014 175
Astellas Pharma Inc. - Pipeline by Molecule Type, 2014 176
Astellas Pharma Inc. - Pipeline Products by Mechanism of Action, 2014 178
Astellas Pharma Inc. - Recent Pipeline Updates, 2014 181
Astellas Pharma Inc. - Dormant Developmental Projects,2014 225
Astellas Pharma Inc. - Discontinued Pipeline Products, 2014 227
Astellas Pharma Inc., Other Locations 239
Astellas Pharma Inc., Subsidiaries 240
Astellas Pharma Inc., Key Manufacturing Facilities 245